肝硬化患者何时使用抗生素？循证依据。
When to use antibiotics in the cirrhotic patient? The evidence base.
作者信息
Anastasiou Jiannis, Williams Roger
机构信息
Second Department of Gastroenterology, Evangelismos Hospital, Athens, Greece (Jiannis Anastasiou).
Institute of Hepatology, Foundation for Liver Research, London (Roger Williams).
出版信息
Ann Gastroenterol. 2013;26(2):128-131.
Abstract
Bacterial infections are very common in advanced cirrhosis and are a leading cause of death of these patients. Early and appropriate empirical antibiotic treatment of infection is essential in determining patient's outcome. A strategy of careful restriction of prophylactic antibiotics to the high-risk populations could contribute to the reduction of multidrug resistant bacteria. This article reviews and reports the current knowledge in the use of antibiotics in the cirrhotic patient.
摘要
细菌感染在晚期肝硬化中非常常见，是这些患者死亡的主要原因。对感染进行早期且恰当的经验性抗生素治疗对于决定患者的预后至关重要。对高危人群谨慎限制预防性抗生素的使用策略有助于减少多重耐药菌。本文综述并报告了目前关于肝硬化患者使用抗生素的知识。
相似文献
1
When to use antibiotics in the cirrhotic patient? The evidence base.肝硬化患者何时使用抗生素？循证依据。
Ann Gastroenterol. 2013;26(2):128-131.
2
Management of bacterial infections in cirrhosis.肝硬化细菌感染的管理。
J Hepatol. 2012;56 Suppl 1:S1-12. doi: 10.1016/S0168-8278(12)60002-6.
3
The new epidemiology of nosocomial bacterial infections in cirrhosis: therapeutical implications.肝硬化患者医院获得性细菌感染的新流行病学：治疗意义
Hepatol Int. 2013 Mar;7(1):72-9. doi: 10.1007/s12072-012-9396-x. Epub 2012 Aug 14.
4
Multidrug-resistant bacterial infections in patients with liver cirrhosis in a tertiary referral hospital.一家三级转诊医院中肝硬化患者的多重耐药细菌感染
Gastroenterol Hepatol. 2019 Apr;42(4):228-238. doi: 10.1016/j.gastrohep.2018.07.017. Epub 2018 Oct 17.
5
Antibiotic prophylaxis in cirrhosis: Good and bad.肝硬化的抗生素预防：好与坏。
Hepatology. 2016 Jun;63(6):2019-31. doi: 10.1002/hep.28330. Epub 2016 Jan 11.
6
Changing options for prevention and treatment of infections in cirrhosis.肝硬化感染预防与治疗的选择变化
Curr Treat Options Gastroenterol. 2014 Jun;12(2):256-67. doi: 10.1007/s11938-014-0017-8.
7
The spread of multi drug resistant infections is leading to an increase in the empirical antibiotic treatment failure in cirrhosis: a prospective survey.多重耐药感染的传播导致肝硬化患者经验性抗生素治疗失败率上升：一项前瞻性调查。
PLoS One. 2015 May 21;10(5):e0127448. doi: 10.1371/journal.pone.0127448. eCollection 2015.
8
Bacterial Infection in Patients with Cirrhosis: Don't Get Bugged to Death.肝硬化患者的细菌感染：别被细菌搞死。
Dig Dis Sci. 2020 Jan;65(1):31-37. doi: 10.1007/s10620-019-05943-6.
9
Infections complicating cirrhosis.肝硬化合并感染。
Liver Int. 2018 Feb;38 Suppl 1:126-133. doi: 10.1111/liv.13645.
10
Antibiotic prophylaxis for spontaneous bacterial peritonitis in cirrhotic patients with ascites, without gastro-intestinal bleeding.肝硬化腹水且无胃肠道出血患者自发性细菌性腹膜炎的抗生素预防
Cochrane Database Syst Rev. 2009 Apr 15(2):CD004791. doi: 10.1002/14651858.CD004791.pub2.
引用本文的文献
1
Exploring the diversity of blood microbiome during liver diseases: Unveiling Novel diagnostic and therapeutic Avenues.探索肝脏疾病期间血液微生物组的多样性：揭示新的诊断和治疗途径。
Heliyon. 2023 Oct 30;9(11):e21662. doi: 10.1016/j.heliyon.2023.e21662. eCollection 2023 Nov.
2
Bacterial Infections in Patients with Liver Cirrhosis in an Internal Medicine Department.内科肝硬化患者的细菌感染
GE Port J Gastroenterol. 2019 Aug;26(5):324-332. doi: 10.1159/000494568. Epub 2018 Dec 17.
3
Antimicrobial-Induced Cytopenia and Bone Marrow Hypocellularity in Patients with Cirrhosis.肝硬化患者中抗菌药物诱发的血细胞减少和骨髓细胞减少
Bone Marrow Res. 2018 May 14;2018:4029648. doi: 10.1155/2018/4029648. eCollection 2018.
4
Sepsis in cirrhosis: emerging concepts in pathogenesis, diagnosis and management.肝硬化中的脓毒症：发病机制、诊断及管理的新观念
Hepatol Int. 2016 Nov;10(6):871-882. doi: 10.1007/s12072-016-9753-2. Epub 2016 Jul 15.
本文引用的文献
1
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).利福昔明可改善轻微肝性脑病患者的心理测量学表现和健康相关生活质量（RIME 试验）。
Am J Gastroenterol. 2011 Feb;106(2):307-16. doi: 10.1038/ajg.2010.455. Epub 2010 Dec 14.
2
Rifaximin improves driving simulator performance in a randomized trial of patients with minimal hepatic encephalopathy.利福昔明可改善轻微肝性脑病患者随机试验中的驾驶模拟器性能。
Gastroenterology. 2011 Feb;140(2):478-487.e1. doi: 10.1053/j.gastro.2010.08.061. Epub 2010 Sep 21.
3
Drug therapy: rifaximin.药物治疗：利福昔明。
Hepatology. 2010 Oct;52(4):1484-8. doi: 10.1002/hep.23866.
4
EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.欧洲肝脏研究学会肝硬化腹水、自发性细菌性腹膜炎和肝肾综合征管理临床实践指南
J Hepatol. 2010 Sep;53(3):397-417. doi: 10.1016/j.jhep.2010.05.004. Epub 2010 Jun 1.
5
Pentoxifylline does not decrease short-term mortality but does reduce complications in patients with advanced cirrhosis.己酮可可碱并不能降低晚期肝硬化患者的短期死亡率，但确实能减少并发症。
Gastroenterology. 2010 May;138(5):1755-62. doi: 10.1053/j.gastro.2010.01.040. Epub 2010 Jan 25.
6
Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.接受类固醇治疗的重症酒精性肝炎患者的感染：治疗的早期反应是关键因素。
Gastroenterology. 2009 Aug;137(2):541-8. doi: 10.1053/j.gastro.2009.04.062. Epub 2009 May 13.
7
Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.利福昔明与不可吸收双糖治疗肝性脑病的Meta分析
Eur J Gastroenterol Hepatol. 2008 Nov;20(11):1064-70. doi: 10.1097/MEG.0b013e328302f470.
8
Genetic background of Escherichia coli isolates from patients with spontaneous bacterial peritonitis: relationship with host factors and prognosis.自发性细菌性腹膜炎患者分离出的大肠杆菌的遗传背景：与宿主因素及预后的关系
Clin Microbiol Infect. 2008 Nov;14(11):1034-40. doi: 10.1111/j.1469-0691.2008.02088.x.
9
Ciprofloxacin in primary prophylaxis of spontaneous bacterial peritonitis: a randomized, placebo-controlled study.环丙沙星用于自发性细菌性腹膜炎的一级预防：一项随机、安慰剂对照研究。
J Hepatol. 2008 May;48(5):774-9. doi: 10.1016/j.jhep.2008.01.024. Epub 2008 Feb 14.
10
Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis.肝硬化患者食管胃静脉曲张及曲张静脉出血的预防与管理
Hepatology. 2007 Sep;46(3):922-38. doi: 10.1002/hep.21907.
Zotero 插件